US Patent 6,235,735: Aprepitant Method-of-Use Claims, Expiration, and Patent Landscape

US Patent 6,235,735 covers methods of using aprepitant, the active ingredient in Emend, to prevent or treat chemotherapy-induced nausea and vomiting, radiation-induced emesis, and postoperative nausea and vomiting. The strongest disclosed claims are method-of-treatment claims requiring administration of the specified aprepitant compound or its pharmaceutically acceptable salt.

The patent’s nominal US term ended on February 7, 2017, subject to any applicable patent-term adjustment or pediatric extension. FDA-approved generic aprepitant products subsequently entered through the Abbreviated New Drug Application pathway. Because aprepitant is a small molecule, biosimilar regulation does not apply.

What compound does US Patent 6,235,735 protect?

The compound identified in claims 1 and 17 is aprepitant, also known as MK-0869.

Aprepitant is a selective neurokinin-1, or NK1, receptor antagonist. Its chemical structure is commonly described as:

5-([(2R,3S)-2-((1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy)-3-(4-fluorophenyl)-4-morpholinyl]methyl)-1,2-dihydro-3H-1,2,4-triazol-3-one.

Its molecular formula is C23H21F7N4O3. The compound is marketed orally as Emend by Merck & Co. for prevention of acute and delayed chemotherapy-induced nausea and vomiting in combination with other antiemetic agents.

Item	Data
Patent	US 6,235,735
Patent type	Therapeutic method-of-use patent
Active ingredient	Aprepitant
Development code	MK-0869
Original developer	Merck & Co.
Core receptor	Neurokinin-1 receptor
Key indications	Chemotherapy-induced nausea and vomiting, radiation-induced emesis, postoperative nausea and vomiting
Issue date	May 22, 2001
Earliest relevant nonprovisional filing	February 7, 1997
Nominal expiration	February 7, 2017
FDA product	Emend
Regulatory pathway for generics	ANDA
Biosimilar pathway	Not applicable

The claim language contains stereochemical limitations. The compound is not covered merely because it is an NK1 antagonist. A potentially infringing product would need to contain the claimed aprepitant stereoisomer, or a pharmaceutically acceptable salt, and be used in a covered treatment method.

What are the independent claims in US 6,235,735?

The supplied claims identify four substantive independent claims: claims 1, 9, 17, and 18.

Claim 1: chemotherapy- and radiation-induced nausea

Claim 1 covers:

administering aprepitant or a pharmaceutically acceptable salt;
to a mammal in need of treatment;
in an effective amount;
to prevent or treat nausea or emesis induced by radiation or a cancer chemotherapeutic agent.

The claim is broad as to the chemotherapy agent. It does not limit the claim to a particular dose, route, schedule, formulation, combination partner, or stage of treatment.

The claim is narrower than a composition claim because it requires conduct by a party administering the compound for the specified therapeutic purpose. It does not cover every manufacture, sale, or possession of aprepitant standing alone.

Claim 17: postoperative nausea and vomiting

Claim 17 covers administration of aprepitant or its pharmaceutically acceptable salt to prevent or treat postoperative nausea and vomiting.

This claim is distinct from claim 1 because it does not require radiation or cancer chemotherapy as the emetic trigger. The postoperative indication creates a separate method-of-use category.

The regulatory and commercial relevance of claim 17 is narrower than its literal therapeutic scope. Emend’s principal FDA-approved use has been chemotherapy-induced nausea and vomiting. A method claim can cover a use broader than the approved product label, but enforcement against unapproved use raises separate questions involving induced infringement, label language, prescriber conduct, and the nature of the accused product’s commercial activity.

Claims 9 and 18: structure-dependent claims

Claims 9 through 16 and claim 18, as supplied, omit the chemical structure displayed in the original patent. The text states only:

claim 9: administration of “a compound which is” followed by an absent structure;
claim 18: administration of “a compound which is” followed by an absent structure.

Those claims cannot be analyzed accurately at the molecular level from the supplied text. Their scope depends entirely on the omitted structural drawings, including stereochemistry, substituent identity, ring system, and salt coverage.

The missing structure is material. Claims 9 and 18 may cover aprepitant, a related NK1 antagonist, or a broader or narrower chemical species. They should not be treated as duplicative of claims 1 and 17 without reference to the issued patent figures.

How do claims 2 through 8 narrow claim 1?

Claims 2 through 8 are dependent claims that add patient or emetic-trigger limitations.

Claim	Added limitation
1	Radiation or cancer-chemotherapy-induced nausea or emesis; aprepitant or salt
2	Mammal is a human
3	Emesis is radiation-induced
4	Chemotherapy agent is cisplatin
5	Chemotherapy agent is cyclophosphamide
6	Chemotherapy agent is doxorubicin
7	Chemotherapy agent is daunorubicin
8	Chemotherapy agent is etoposide

Claims 4 through 8 are particularly narrow because each identifies a specific chemotherapy agent. A product or treatment falling within claim 1 may not fall within claims 4 through 8 unless the relevant chemotherapy agent is also present.

The dependent claims provide fallback positions. If a court were to construe claim 1 narrowly or invalidate part of its scope, the patent owner could still rely on the more specific chemotherapy-agent claims, assuming the underlying claim elements remain valid and enforceable.

What is the infringement scope of the aprepitant claims?

Product composition alone is not enough

Claims 1 and 17 are method claims. They require:

a covered compound;
administration to a mammal;
an effective amount; and
a covered therapeutic purpose.

A manufacturer generally does not infringe solely by making aprepitant if the asserted claim requires a treatment method. Potential liability may arise through direct treatment, induced infringement, contributory infringement, or other theories depending on the facts and applicable law.

The salt limitation is commercially important

The claims expressly include “a pharmaceutically acceptable salt.” The relevant infringement analysis therefore extends beyond the neutral parent compound to pharmaceutically acceptable salt forms, provided the salt contains the claimed active molecular entity and satisfies the claim construction adopted by the court.

This language does not automatically cover every prodrug, metabolite, formulation excipient, or chemically modified derivative. A prodrug such as fosaprepitant requires separate claim analysis because it is a distinct chemical entity and is administered intravenously after formulation as a prodrug.

The indication limitation creates carve-out issues

A generic aprepitant label that includes chemotherapy-induced nausea and vomiting presents a direct method-of-use exposure if the relevant claim remains enforceable. A generic label that omits a patented indication may reduce, but does not necessarily eliminate, induced-infringement risk. Courts examine the complete label, promotional conduct, prescribing environment, and whether the remaining indications inevitably encourage the patented use.

What chemotherapy uses are protected?

The patent specifically identifies five chemotherapeutic agents:

cisplatin;
cyclophosphamide;
doxorubicin;
daunorubicin; and
etoposide.

These agents represent different classes and emetogenic profiles. Cisplatin is strongly emetogenic, while the other listed agents may contribute to acute or delayed nausea depending on dose and treatment combination.

Claim 1 is not limited to those five agents. Its reference to a “cancer chemotherapeutic agent” potentially reaches other chemotherapy agents, subject to claim construction and proof that the nausea or emesis was induced by the relevant agent.

What is the FDA and Orange Book status?

Emend was approved by FDA in 2003 for prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, in combination with other antiemetics. FDA later expanded aprepitant labeling to additional chemotherapy settings and pediatric use. The product is supplied in oral dosage forms, including capsules and a newer oral suspension presentation under the Emend brand.

The Orange Book historically listed patents associated with Emend and aprepitant. US 6,235,735 was a method-of-use patent rather than the primary chemical-composition patent. Orange Book listings are relevant to ANDA certification and patent litigation, but an Orange Book listing does not by itself establish validity or infringement.

Regulatory exclusivity versus patent exclusivity

FDA approval exclusivity and patent exclusivity are separate:

Exclusivity type	Relevance to aprepitant
New chemical entity exclusivity	Applied at initial approval and expired years before patent expiry
Pediatric exclusivity	May extend listed exclusivity or patent protection by six months where statutory requirements are met
Orange Book patent term	Controlled generic certification and potential litigation
ANDA exclusivity	May apply to a first generic challenger, depending on the certification and approval history
Biologic exclusivity	Not applicable

The practical generic-entry date was controlled by the remaining patent estate, settlement positions, FDA approval timing, and any pediatric extension rather than by the original five-year new chemical entity period.

When did US 6,235,735 lose exclusivity?

The patent’s nominal expiration date was February 7, 2017. Any enforceable extension would have depended on the patent record and statutory adjustments. A six-month pediatric extension, if applicable to the listed patent, could have moved the effective endpoint into 2017.

The patent is no longer a live barrier to a new US generic launch based on ordinary patent-term enforcement. Current commercial risk instead centers on other patents, formulation rights, manufacturing patents, regulatory exclusivity, and product-specific litigation.

What other patents protected aprepitant?

The aprepitant estate included several patent categories.

Chemical-composition patents

The foundational patents covered aprepitant and related NK1 antagonist compounds. Composition claims generally provided the strongest exclusionary position because they reached the active ingredient regardless of the specific approved use.

Method-of-use patents

US 6,235,735 focused on antiemetic treatment. Its claims covered chemotherapy-induced, radiation-induced, and postoperative nausea and vomiting.

Formulation and dosage-form patents

Later filings addressed:

oral capsule formulations;
particle-size and solid-state properties;
suspension formulations;
intravenous formulations;
prodrug approaches involving fosaprepitant;
manufacturing processes and intermediate compounds.

Formulation claims generally have narrower scope than composition claims. They can remain commercially significant after an active-ingredient patent expires if the generic must use the protected formulation to obtain a meaningful regulatory or commercial position.

Fosaprepitant patents

Fosaprepitant dimeglumine is an intravenous prodrug of aprepitant marketed as Emend for Injection. Its patent position is separate from the oral aprepitant method claims. A manufacturer seeking to market injectable fosaprepitant must evaluate the prodrug composition, salt, formulation, lyophilization, manufacturing, and method-of-use patents independently.

Which companies challenged aprepitant exclusivity?

Aprepitant generic development involved multiple ANDA applicants and generic manufacturers. Publicly reported market participants have included Teva, Dr. Reddy’s Laboratories, Sandoz, and Glenmark, among others.

Paragraph IV certification under the Hatch-Waxman Act can trigger patent litigation under 35 U.S.C. §271(e)(2). Such litigation typically concerns:

whether the ANDA product practices the asserted claims;
whether the patent claims are valid;
whether the claims are enforceable;
whether a proposed label induces infringement;
and the date on which the generic may launch.

Generic aprepitant entered after the principal patent barriers had expired or been resolved. The existence of a Paragraph IV certification does not itself invalidate a patent. It creates a statutory basis for litigation and can impose a 30-month FDA approval stay under the applicable conditions.

What litigation issues were most important?

For US 6,235,735, the central litigation issues would have included:

Claim construction

The parties would likely dispute:

the meaning of “effective amount”;
what qualifies as a cancer chemotherapeutic agent;
whether the induced nausea or emesis must be directly caused by the claimed agent;
the scope of “pharmaceutically acceptable salt”;
and whether postoperative nausea claims require a particular perioperative administration schedule.

Written description and enablement

A broad method claim covering radiation and a broad class of cancer chemotherapeutic agents can invite written-description and enablement challenges. The patent specification would be evaluated for representative disclosure and technical teaching across the claimed scope.

Obviousness

A challenger could argue that NK1 antagonism, antiemetic treatment, or the specific aprepitant use was obvious based on earlier compounds and animal or clinical data. The patent owner would rely on compound selection, stereochemistry, potency, selectivity, antiemetic results, and unexpected clinical properties.

Induced infringement

Generic labels create the principal commercial exposure for method-of-use claims. The analysis depends on whether the label instructs use for a patented indication or whether the patented use is an inevitable consequence of the approved directions.

How strong is the patent estate?

US 6,235,735 was commercially meaningful but weaker than a valid, unexpired composition patent.

Factor	Assessment
Claim type	Method of use
Chemical specificity	High for claims 1 and 17
Indication breadth	Moderate to broad in claim 1
Salt coverage	Expressly included
Formulation coverage	Not the primary focus
Direct product blocking power	Limited compared with composition claims
Generic-label exposure	Material during patent term
Current enforceability	Expired based on nominal term
Biosimilar relevance	None
Residual commercial relevance	Historical patent landscape and claim interpretation

The strongest claims were likely claims 1 and 17 because they directly identify aprepitant and cover commercially important antiemetic uses. Claims 4 through 8 are narrower but provide additional specificity. Claims 9 through 16 and 18 cannot be ranked without the missing chemical structures.

What generic launch scenarios existed?

During the patent term, an aprepitant ANDA applicant had several potential routes:

Paragraph III certification, delaying approval until patent expiration.
Paragraph IV certification, challenging validity, enforceability, or infringement.
A section viii statement omitting a patented method from the proposed label, where FDA labeling permitted a carve-out.
Settlement with the patent holder providing an agreed launch date.
Launch after expiration of the composition, method, formulation, and pediatric-exclusivity barriers.

A section viii carve-out would have been difficult if the patented method was inseparable from the approved use or if the generic label still encouraged the patented indication.

What geographic coverage did the patent have?

US 6,235,735 provided rights only in the United States. Corresponding patent-family members may have covered Europe, Canada, Japan, and other jurisdictions, but each jurisdiction required separate validity, term, claim-scope, and regulatory analysis.

A US expiration did not eliminate foreign rights. Conversely, expiration or invalidity of a foreign counterpart did not affect the US patent.

What manufacturing and IP barriers remained after expiration?

After expiration of the principal US method claims, competitive barriers could remain in:

API process chemistry;
chiral resolution or stereoselective synthesis;
impurity control;
polymorph and particle-size management;
dissolution and bioequivalence;
oral suspension technology;
injectable prodrug manufacturing;
sterile manufacturing;
supply-chain qualification;
and trademark or trade-dress restrictions.

These are commercial and regulatory barriers rather than substitutes for an expired composition patent. They can affect launch timing, cost of goods, and product reliability without preventing all generic entry.

Key Takeaways

US 6,235,735 is primarily an aprepitant method-of-use patent.
Claims 1 and 17 cover aprepitant or a pharmaceutically acceptable salt for chemotherapy-, radiation-, and postoperative nausea and vomiting.
Claims 4 through 8 narrow claim 1 to cisplatin, cyclophosphamide, doxorubicin, daunorubicin, and etoposide.
The patent’s nominal expiration date was February 7, 2017, subject to any applicable term adjustment or pediatric extension.
The patent was more limited than a composition patent because it required administration for a covered therapeutic purpose.
Generic aprepitant entered through the ANDA pathway, not the biosimilar pathway.
Formulation, prodrug, process, and solid-state patents required separate analysis.
Claims 9 through 16 and 18 cannot be fully assessed because the chemical structures are absent from the supplied claim text.

FAQs

Is US 6,235,735 an aprepitant composition patent?

No. It is principally a method-of-use patent. The claims require administering aprepitant or a covered related compound for specified antiemetic purposes.

Does US 6,235,735 cover fosaprepitant?

Not automatically. Fosaprepitant is a distinct prodrug. Coverage depends on the actual claim language and whether the patent claims the prodrug, its salt, its formulation, or a method that legally encompasses administration of that compound.

Can a generic aprepitant manufacturer avoid the patent by changing the dosage?

Not necessarily. Claims 1 and 17 do not specify a particular dosage. Changing dose, capsule size, or administration schedule would not avoid infringement if all claim elements remain satisfied.

Does a patent expiration eliminate FDA exclusivity?

No. Patent expiration and FDA regulatory exclusivity are separate. A generic may still face regulatory requirements, ANDA review, first-filer issues, or other unexpired patents after this patent expires.

What is the main unresolved issue in claims 9 and 18?

The chemical structures are missing from the supplied text. Without those structures, the identity, stereochemistry, salt scope, and relationship to aprepitant cannot be determined accurately.

References

U.S. Patent No. 6,235,735. (2001). Methods for the prevention or treatment of nausea and emesis. U.S. Patent and Trademark Office.
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.
U.S. Food and Drug Administration. (2024). Emend (aprepitant) prescribing information. Merck & Co.
U.S. Food and Drug Administration. (2024). Approved drug products and abbreviated new drug applications. FDA.
U.S. Code, 35 U.S.C. §§ 154, 271(e)(2), and 156.
U.S. Code, 21 U.S.C. § 355(j).

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	0734381	⤷ Start Trial	91069	Luxembourg	⤷ Start Trial
European Patent Office	0734381	⤷ Start Trial	300146	Netherlands	⤷ Start Trial
European Patent Office	0734381	⤷ Start Trial	PA2004002	Lithuania	⤷ Start Trial
European Patent Office	0734381	⤷ Start Trial	SPC/GB04/011	United Kingdom	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 6,235,735